Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis-Reference-Cited by-同舟云学术

Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis

Published:2015-04-13 Issue:3 Volume:11 Page:253-261
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Luo Long¹²,Hu Qian¹,Jiang Jun-xia¹,Yang Xing¹,Dinglin Xiao-xiao¹,Lin Xiao¹,Yao He-rui¹

Affiliation:

1. Department of Oncology; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangzhou China

2. Department of Oncology; Yiyang Central Hospital of Hunan Province; Yiyang China

Funder

Ministry of Education of China

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12359/fullpdf

Reference17 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

3. Non-small cell lung cancer;Ettinger;J Natl Compr Canc Netw,2012

4. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution;Buccheri;Eur J Cancer,1996

5. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer;Ruckdeschel;J Clin Oncol,1986

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Populations particulières : patients de performance status 2 ou plus;Revue des Maladies Respiratoires Actualités;2023-10

2. Populations particulières : patients de Performance Status 2 ou plus;Revue des Maladies Respiratoires Actualités;2022-10

3. International consensus on severe lung cancer—the first edition;Translational Lung Cancer Research;2021-06

4. 2020 Innovation-Based Optimism for Lung Cancer Outcomes;The Oncologist;2020-12-20

5. Populations particulières : patients de Performance Status 2 ou plus;Revue des Maladies Respiratoires Actualités;2020-10